Needham downgraded Avidity Biosciences (RNA) to Hold from Buy after the company entered into a definitive merger agreement to be acquired by Novartis (NVS) for $72 per share in cash. The firm says it doesn’t expect a competitive bidding process to occur before the transaction closes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences downgraded to Market Perform from Strong Buy at Raymond James
- Avidity Biosciences downgraded to Market Perform from Outperform at Bernstein
- Avidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright
- M&A News: Novartis to Acquire Avidity Biosciences in $12B Deal
- Novartis agrees to acquire Avidity for $72 per share in cash